Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...
Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial ...
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...
Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback